Total Payments
$552,895
2024 Payments
$6,623
Companies
8
Transactions
81
Payment Breakdown by Category
Research$547,682 (99.1%)
Travel$3,947 (0.7%)
Food & Beverage$1,247 (0.2%)
Gifts$20.00 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $547,682 | 48 | 99.1% |
| Travel and Lodging | $3,947 | 15 | 0.7% |
| Food and Beverage | $1,247 | 17 | 0.2% |
| Gift | $20.00 | 1 | 0.0% |
Payments by Type
Research
$547,682
48 transactions
General
$5,213
33 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valneva Austria GmbH | $503,424 | 23 | $0 (2022) |
| Eli Lilly and Company | $25,713 | 15 | $0 (2024) |
| TARO PHARMACEUTICALS USA, INC. | $14,170 | 4 | $0 (2017) |
| PFIZER INC. | $4,788 | 6 | $0 (2024) |
| Allergan Inc. | $1,777 | 6 | $0 (2017) |
| Merck Sharp & Dohme LLC | $1,363 | 13 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,119 | 13 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $541.76 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,623 | 4 | Eli Lilly and Company ($3,388) |
| 2023 | $1,420 | 3 | Eli Lilly and Company ($1,420) |
| 2022 | $503,126 | 26 | Valneva Austria GmbH ($502,280) |
| 2021 | $70.00 | 2 | Eli Lilly and Company ($50.00) |
| 2020 | $1,011 | 3 | Eli Lilly and Company ($1,011) |
| 2019 | $14,514 | 3 | Eli Lilly and Company ($13,370) |
| 2018 | $8,563 | 25 | Eli Lilly and Company ($5,645) |
| 2017 | $17,568 | 15 | TARO PHARMACEUTICALS USA, INC. ($14,170) |
All Payment Transactions
81 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/05/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: VACCINE | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,218.00 | Research |
| Study: A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,170.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | ||||||
| 08/27/2024 | PFIZER INC. | ABRYSVO (Biological) | — | In-kind items and services | $3,200.00 | Research |
| Study: RSV VACCINE PROT SUBUNIT PREF 2V CLINICAL PUBLICATION PROGRAM • Category: VACCINES | ||||||
| 06/21/2023 | Eli Lilly and Company | — | — | In-kind items and services | $535.01 | Research |
| Study: A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | ||||||
| 05/21/2023 | Eli Lilly and Company | — | — | In-kind items and services | $600.01 | Research |
| Study: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $285.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 12/30/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $165,504.25 | Research |
| Study: IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY. | ||||||
| 11/30/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $31,125.80 | Research |
| Study: IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY. | ||||||
| 11/25/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $8,538.58 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 10/02/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $4,462.15 | Research |
| Study: IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY. | ||||||
| 08/30/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $7,011.95 | Research |
| Study: IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY. | ||||||
| 08/08/2022 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: VACCINE | ||||||
| 07/31/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $8,286.85 | Research |
| Study: IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY. | ||||||
| 07/19/2022 | Merck Sharp & Dohme LLC | CAPVAXIVE (Biological) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: VACCINE | ||||||
| 06/30/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $29,960.15 | Research |
| Study: IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY. | ||||||
| 06/27/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $10,700.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | ||||||
| 05/31/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $23,149.60 | Research |
| Study: IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY. | ||||||
| 05/24/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $10,800.00 | Research |
| Study: Alternative schedule study for VLA15, a MULTIVALENT recombinant OspA BASED vaccine CANDIDATE against Lyme borreliosis, IN HEALTHY ADULTS AGED 18 to 65 years - a Randomized, controlled, observer-blind phase 2 study. | ||||||
| 05/03/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $8,030.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $428.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $298.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $50.00 | Research |
| Study: PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | ||||||
| 04/28/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $4,129.65 | Research |
| Study: IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY. | ||||||
| 04/26/2022 | Valneva Austria GmbH | — | — | Cash or cash equivalent | $4,868.21 | Research |
| Study: A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY. | Valneva Austria GmbH | $422,803 | 11 |
| A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | Valneva Austria GmbH | $32,848 | 5 |
| Alternative schedule study for VLA15, a MULTIVALENT recombinant OspA BASED vaccine CANDIDATE against Lyme borreliosis, IN HEALTHY ADULTS AGED 18 to 65 years - a Randomized, controlled, observer-blind phase 2 study. | Valneva Austria GmbH | $25,490 | 2 |
| A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | Valneva Austria GmbH | $21,139 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN ADULTS WITH TREATMENT-RESISTANT MIGRAINE - THE CONQUER STUDY | Eli Lilly and Company | $19,015 | 2 |
| TaroAZAG 1533 | TARO PHARMACEUTICALS USA, INC. | $14,170 | 4 |
| RSV VACCINE PROT SUBUNIT PREF 2V CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | Eli Lilly and Company | $2,218 | 1 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $1,326 | 4 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $1,170 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $683.00 | 2 |
| A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | Eli Lilly and Company | $600.01 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY | Eli Lilly and Company | $570.49 | 2 |
| Safety,Immunogenicity, and Dose ranging Study of Inactivqatzed Zika Virus vaccine in Healthy Adults | Takeda Pharmaceuticals U.S.A., Inc. | $541.76 | 1 |
| A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | Eli Lilly and Company | $535.01 | 1 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $451.00 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | Eli Lilly and Company | $298.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $285.00 | 1 |
| A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | Eli Lilly and Company | $235.84 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | Eli Lilly and Company | $52.80 | 1 |
| PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | Eli Lilly and Company | $50.00 | 1 |
About Dr. Matthew Davis, MD
Dr. Matthew Davis, MD is a Family Medicine healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700968401.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Davis, MD has received a total of $552,895 in payments from pharmaceutical and medical device companies, with $6,623 received in 2024. These payments were reported across 81 transactions from 8 companies. The most common payment nature is "" ($547,682).
Ad
Practice Information
- Specialty Family Medicine
- Location Rochester, NY
- Active Since 10/20/2006
- Last Updated 07/08/2007
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1700968401
Products in Payments
- Topicort Spray 0.25% (Drug) $14,170
- ABRYSVO (Biological) $3,200
- TRUMENBA (Biological) $1,568
- V181 (Biological) $1,258
- CAPVAXIVE (Biological) $35.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Rochester
Diana Widicus, Md, MD
Family Medicine — Payments: $68,853
Family Medicine $68,853
Dr. Michael Mcmullen, M.d, M.D
Family Medicine — Payments: $30,924
Family Medicine $30,924
Dr. Carolyn Stern, Md, MD
Family Medicine — Payments: $15,023
Family Medicine $15,023
Dr. Edith Grannum, Md, MD
Family Medicine — Payments: $10,976
Family Medicine $10,976
Mitchell Pfeiffer, Md, MD
Family Medicine — Payments: $9,925
Family Medicine $9,925
Dr. Bruce Hira, Md, MD
Family Medicine — Payments: $9,189
Family Medicine $9,189